Teriparatide · source year
5 selected, source-linked Teriparatide records carrying a 2019 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
5 selected records.
2 represented types.
5 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01440803 at 2026-07-30T20:42:14.438Z. Its registry update date was 2019-12-11, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 211939 with status AP dated 2019-10-04, and names teriparatide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01709110 at 2026-07-30T20:45:58.285Z. Its registry update date was 2019-09-23, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02239523 at 2026-07-30T20:53:39.666Z. Its registry update date was 2019-04-05, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02472782 at 2026-07-30T20:57:18.711Z. Its registry update date was 2019-01-10, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗